I am a bit of a connoisseur of orthopedic startups. Been doing this for 40 years.
I can usually pick the early winners (like an OSSIO) based on the early leadership, the clinical need, the technology niche, the funding potential, regulatory pathway, etc.
Today, I am calling out Arbutus Medical as a new ortho startup poised for tremendous growth.
website – https://arbutusmedical.com/
Listen/Watch interview last week with Mark Copeland – Arbutus Medical – Sutures and Cents / Season 3 Ep. 5
The Big Picture: Streamlining Surgery Outside the OR
Arbutus Medical is carving out a new category—”Surgery Outside the OR™”—targeting inefficient bedside procedures in ERs, clinics, and low-resource settings. Founded in 2014 from a Vancouver General Hospital collab, they’ve enabled 136,000+ surgeries globally.
Their secret sauce? Affordable, sterile-ready tools that end the “scavenger hunt” chaos, saving hospitals $500M+ annually in US ER delays alone.
Looking at just the first 8 indications we’ve assessed, there is potential to streamline 8M+ surgeries per year in the US and win back $500M+ annually for US ERs by averting delays. Of 155M ED visits in the US annually, 64M patients will receive at least one procedure, so Arbutus is just scratching the surface with these first 8 indications.
With strong beachheading in US traumas (starting with skeletal traction), they’re expanding to wide-awake hand/foot surgeries and field medicine.
From humanitarian roots (partners like MSF, SIGN Fracture Care, Canadian Armed Forces) to commercial dominance, Arbutus has pivoted smart. Started with DrillCover™ tech for repurposing DeWalt/Makita drills in Uganda—now it’s FDA-cleared for US Level 1s, slashing costs vs. $30K power trays. Tagline: “We streamline surgery outside the OR.”
Products: End-to-End Workflow Solutions
Each kit is a reusable/consumable combo—drills free on placement, disposables priced per kit (e.g., TrakPak is their flagship kit)—delivering fixed costs, zero CSP burden, and happier staff/patients
- TrakPak® (Launched 2021): Flagship for skeletal traction (femur/pelvis fractures, 61K US cases/year). All-in-one sterile kit: SteriTrak® pin, QuikBow® tension bow, accessories + DrillCover PRO/HEX drill. Ends 45min-3hr delays. The average hospital can save an estimated $549/patient* vs. old way (scavenger hunt + sterilization = $1,444). (*Savings can vary by facility.) Demo shows bedside setup in minutes on standard beds—no special frames needed. Adopted at Harborview (40+ residency programs trained) and Shock Trauma as standard of care. Podcast highlight: Reduces 60-90min hunts to 15min procedures.
- Digit Revision SwiftKit™ (Launched Nov 2024): For fingertip/toe amputations (65K cases), nailbed repairs (190K). Pre-sterilized tools fix “disaster” ER revisions—e.g., wrong-sized rongeurs from massive OR trays. 30min delays gone; making strong inroads and standardized at Curtis National Hand Center (500+ cases/year).
- Pipeline: Nailbed Repair, Small Bone Fracture Pinning, Foot Ulcer Debridement, Hand/Facial Laceration, Cervical Traction… and more. The company is initially focused on hand-specific indications. Plus innovations like QuikRev™, QuikLift™, BlueWave™ for more ER procedures. IP moat: 3 patents issued, 13 pending on DrillCover Technology™, sterile-ready drills, plant-based/recyclable materials.
Business case?
Old way: $900 scavenger hunt + $420 sterilization + $124 supplies = CHAOS.
The Arbutus way: Fixed efficiency, wins back $549/patient, boosts ED throughput (155M US visits/year, 64M procedures).
Innovation Engine: Speed, Simplicity, Greenfield Focus
Arbutus is a lean machine—sub-12mo dev cycles, 18-person team iterating via surgeon feedback.
Platform pillars: Sterile-ready drills (Gen 1/2), innovative instruments (e.g., QuickBow changes pull direction, skips traction beds), streamlined kits.
From global health (14 joint replacements in 5 days, per Dr. Kelly Johnston) to US ERs, they’ve solved “borrowing” pains.
Podcast insight: Born from Uganda mission, scaled via Baltimore surgeon tip—now “Paradigm” platform for 8+ indications beyond traction.
Strategic edge: Resident-led flywheel—facilities standardize, residents train peers. Harborview adoption curve: Cumulative “referrers” drive organic growth. No real competition; rep-light model frees you for more closes.
Funding & Financials: Fresh Fuel for Scale
Significant institutional growth financing closed (oversubscribed) in January 2026 — stay tuned for press-release.
Key highlights:
- Goal to reach $20M/yr in revenue by 2028
- 100% 3yr CAGR
- “Healthy” gross margin profile in-line or better than public comps
- Capital efficient model + controlled burn rate. EBITDA on plan.
- ISO13485/MDSAP certified
Sales Trajectory: From Beachhead to Monopoly
85+ facilities (up from ~50 in 2024 – substantial YoY growth), including strong penetration at US Level 1 trauma centers. Wins include Kaiser (third-largest US system, monthly reorders), Johns Hopkins, Mass General, Yale, and standard of care for skeletal traction at Harborview and Shock Trauma. Standardized at Curtis for SwiftKit. Challenges: Longer VACs (IRA/econ squeezes), but funding fuels acceleration with hires.
Transitioning to hybrid sales: Internal directors + 1099s. Podcast: Expanding “ED-ready” category
Leadership Team: Proven Executors
- Lawrence Buchan (CEO, Co-founder): 15+ yrs ortho research/commercialization. Podcast: Drove Uganda-to-US pivot.
- Mike Cancilla (Engineering/Quality, Co-founder): 15+ yrs ortho devices.
- Livleen Veslemes (Operations): Multi-time med device CFO/CEO.
- Brian Voong (Finance, CPA): Led Canadian finance for major players.
- Geoff Borgmann (Sales): Managed ortho power tools; drives US expansion.
- Jeff Kennelly (Manufacturing): 15+ yrs med devices.
- Board: Tom Urban (Chair), Marie-Claude Jacques, Dr. Ray Muzyka, Paul Geyer.
- Surgeon Advisory Board: Multi-specialty experts.
Wanted: a killer Region Sales Manager in the NE
If you’re ready to help build Arbutus from the Midwest sales region or the Northeast sales region, prove it to me a short email…. and we just might have a chat about it.
Email tigerbuford@gmail.com with your resume + a three-sentence proof you read this.